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Abstract
Antibiotic resistance is recognized as a growing healthcare problem. To address this issue, one strategy is to thwart the
causal mechanism using an adjuvant in partner with the antibiotic. Aminoglycosides are a class of clinically important
antibiotics used for the treatment of serious infections. Their usefulness has been compromised predominantly due to drug
inactivation by aminoglycoside-modifying enzymes, such as aminoglycoside phosphotransferases or kinases. These kinases
are structurally homologous to eukaryotic Ser/Thr and Tyr protein kinases and it has been shown that some can be inhibited
by select protein kinase inhibitors. The aminoglycoside kinase, APH(39)-IIIa, can be inhibited by CKI-7, an ATP-competitive
inhibitor for the casein kinase 1. We have determined that CKI-7 is also a moderate inhibitor for the atypical APH(9)-Ia. Here
we present the crystal structures of CKI-7-bound APH(39)-IIIa and APH(9)-Ia, the first structures of a eukaryotic protein kinase
inhibitor in complex with bacterial kinases. CKI-7 binds to the nucleotide-binding pocket of the enzymes and its binding
alters the conformation of the nucleotide-binding loop, the segment homologous to the glycine-rich loop in eurkaryotic
protein kinases. Comparison of these structures with the CKI-7-bound casein kinase 1 reveals features in the binding
pockets that are distinct in the bacterial kinases and could be exploited for the design of a bacterial kinase specific inhibitor.
Our results provide evidence that an inhibitor for a subset of APHs can be developed in order to curtail resistance to
aminoglycosides.
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Introduction
The waning prospect of an effective treatment for bacterial
infections due to the emergence and spread of resistance to
antibiotics in pathogens has been exacerbated by the lack of novel
antibacterials being introduced to the market [1]. An alternative
and parallel approach in supporting the mitigation of the antibiotic
resistance problem is to develop adjuvants that could interfere with
the mechanism of resistance and hence restore the action of
antibiotics [2]. Such a strategy has been effectively employed to
combat resistance to b-lactams due to b-lactamase activity [3]. For
aminoglycosides, a group of antibiotics used to treat serious
nosocomial infections, the main mechanism of resistance is via the
enzymatic inactivation of the drug by acetyltransferases, nucleo-
tidyltransferases, or phosphotransferases [4]. This implies that
inhibitors of these enzymes could be exploited for the development
of drug-adjuvant therapy [5,6]. Among the three types of
aminoglycoside-modifying enzymes, aminoglycoside phospho-
transferases or kinases (APHs) yield the highest levels of resistance
thereby providing a rationale for focusing inhibitor development
for these specific resistance factors [7].
The investigation of APH inhibitors that target the ATP-binding
pocket was facilitated by the structural similarities between the
aminoglycoside resistance enzyme APH(39)-IIIa and serine/threonine
and tyrosine eukaryotic protein kinases (ePKs), especially in the N-
terminal lobe [8] (Figure 1A,C). It was subsequently shown that
APH(39)-IIIa can be inhibited by protein kinase inhibitors of the
isoquinolinesulfonamide family and they are competitive with ATP-
binding [9]. For example, the protein kinase inhibitor N-(2-
aminoethyl)-5-chloro-isoquinoline-8-sulfonamide (CKI-7) (Figure 1D)
has an inhibition constant of 65 mMf o rA P H ( 3 9)-IIIa. Unfortunately,
these compounds are only able to inhibit the resistance enzymes in vitro
and cannot rescue the function of aminoglycosides in enterococcal
strains harboring the aph(39)-IIIa gene [9]. Nonetheless, this study
identified lead compounds for adjuvant development aimed at
reversing APH mediated resistance to aminoglycosides.
X-ray structures of several members in the APH family have
since been determined [8,10,11,12,13,14]. However, APH(39)-IIIa
remains the most extensively studied due to its broad substrate
spectrum [9,15,16,17,18,19]. The crystal structure of APH(39)-IIIa
in the apo, ADP- or AMP-PNP-bound forms [8,20], as well as its
ternary complex of three structurally dissimilar aminoglycosides
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examined structurally is APH(9)-Ia (e.g. 9% sequence identity with
APH(39)-IIIa). APH(9)-Ia is an atypical APH which phosphory-
lates only one aminoglycoside, spectinomycin, that is distinct from
the other aminoglycoside antibiotics. Its apo, AMP-bound and the
ternary structures have been determined, making it the second
structurally most studied member of the APH family [11].
Combined, these studies reveal that although members of the
APH family share low similarities in sequence and their ligand
specificity varies greatly, their overall three-dimensional fold is
homologous to each other and to that of ePKs (Figure 1A–C).
To further advance the development of APH inhibitors, we
describe here the three-dimensional structure of the APH(39)-IIIa
and APH(9)-Ia in complex with CKI-7 (PDB accession codes 3Q2J
and 3Q2M, respectively). These inhibitor bound crystal structures
of APHs represent the first structures of a eukaryotic protein kinase
inhibitor complexed to enzymes that are not eukaryotic protein
kinases. Comparison of the inhibitor-bound APH(39)-IIIa and
APH(9)-Ia complexes with the nucleotide-bound APH(39)-IIIa and
APH(9)-Ia, as well as the CKI-7-bound casein kinase 1 (CK1)
reveals the different inhibitor binding modes as well as topological
features that could be exploited in the development of inhibitors
with enhanced affinity and selectivity for APH enzymes.
Results and Discussion
Inhibition of APHs by CKI-7
Previously, details on the inhibition of APH(39)-IIIa by CKI-7
have been reported (Ki=66.167.5 mM) [9]. Here we show that
the atypical APH, APH(9)-Ia, is also affected by this protein kinase
inhibitor. Paralleling the APH(39)-IIIa result, CKI-7 was found to
inhibit APH(9)-Ia (Ki=159611 mM) in a competitive fashion with
respect to ATP, although 2.5 times less effectively. These results
suggest that the CKI-7 scaffold may be exploited for the
development of broad-spectrum APH inhibitors. This possibility
is further reinforced by the observation that a third APH enzyme,
APH(20)-Ia is similarly inhibited by this compound (Ki=
87.1617.8 mM) [9]. However, the inhibition constants for CKI-
7 are high, especially when compared to that obtained for the ePK
CK1, which is an order of magnitude lower (Ki=8.5 mM) [22].
Nonetheless, at present CKI-7 is the only compound identified
that is able to inhibit the ATP-binding site of several APH
enzymes.
Crystal structures of APHNCKI-7 complexes
To further examine the suitability of the CKI-7 scaffold for
inhibitor development, we determined the crystal structures of
APH(39)-IIIa and APH(9)-Ia in complex with CKI-7 (Figure 1A,B).
The APH(39)-IIIa-CKI-7 inhibitor complex was crystallized in the
space group P212121 with two inhibitor-bound enzyme molecules
in the asymmetric unit, analogous to the nucleotide bound enzyme
complexes [8,20]. The structure has been refined to 2.15 A ˚ with
an Rcryst of 0.189 and Rfree of 0.235. The CKI-7-bound APH(9)-Ia
complex was crystallized in space group P3121 with one molecule
per asymmetric unit. This structure has been refined to 2.9 A ˚ and
a final Rcryst and Rfree of 0.222 and 0.279, respectively.
Comparison of these crystal structures with the apo, nucleotide-
bound, and aminoglycoside and nucleotide-bound states, available
for both APH(39)-IIIa and APH(9)-Ia, reveals that the CKI-7-
bound enzyme conformations most closely resemble that of the
binary nucleotide-bound states. This is to be expected, as CKI-7 is
competitive with ATP. However, some differences can also be
noted between the APH-CKI-7 bound states and that of the APH-
nucleotide bound states, most notably in the region designated as
the glycine-rich loop in ePKs. In APH(39)-IIIa the homolog of the
glycine-rich loop are residues 21-27 (Figure 2C). In the nucleotide-
bound enzyme structures, the loop is positioned above the
phosphate moieties of the nucleotide [20], whereas, in the
APH(39)-IIIa-CKI-7 structure, the tip of the loop points back into
the phosphate-binding area, delimiting the nucleotide-binding
pocket, reminiscent of what is seen in the apo state of APH(39)-IIIa
[20]. For APH(9)-Ia, this same loop (residues 28–34) also adopts a
different conformation in the APH(9)-Ia-CKI-7 structure com-
pared to the nucleotide-bound state (Figure 2D). In fact, the
conformation observed is comparable to what is observed for
APH(39)-IIIa, i.e. the tip of loop in the CKI-7-bound APH(9)-Ia
also dips into the phosphate-binding area of the nucleotide binding
pocket.
Inhibitor Binding Site
As expected, for both APH(39)-IIIa and APH(9)-Ia, the ATP-
competitive inhibitor CKI-7 occupies the nucleotide-binding
pocket, between the N- and C-terminal lobes. The binding of
the inhibitor did not alter the main or side chain conformation of
any residues lining the binding pocket in either enzyme, except for
the APH homolog of the glycine-rich loop mentioned above. The
isoquinoline ring of the inhibitor is buried in the hydrophobic
adenine-binding cleft (Figure 2A,B) and its position and orienta-
tion mimics that of the adenine ring of the nucleotide
(Figure 2C,D). A principal contact between the isoquinoline or
adenine ring with APH is the stacking interactions conferred by
the aromatic ring side chain of Tyr42 in APH(39)-IIIa and Phe50
in APH(9)-Ia (Figure 2). The residue at this location is conserved as
Figure 1. Crystal structures of CKI-7-bound kinases. (A) APH(39)-
IIIa, (B) APH(9)-Ia, and (C) CK1 (PDB 2CSN). The enzymes are shown in
cartoon representation and the inhibitors are drawn as sticks. (D)
Chemical structure of CKI-7.
doi:10.1371/journal.pone.0019589.g001
CKI-7-Bound Structures of Two APH Enzymes
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well as APH(30) enzymes, and shown to be important for binding
and catalysis [20]. Intriguingly, despite the conserved nature of this
residue, the aromatic side chain of Tyr42 of APH(39)-IIIa points
toward the linker region of the protein whereas the side chain of
Phe50 in APH(9)-Ia points in the opposite direction toward the
ribose- and phosphate-binding pockets (Figure 3A). Accordingly,
the adenine ring of the bound nucleotides adopt distinct
orientations, differing by a rotation of approximately 40u [11].
The corresponding 40u difference is also observed between the
isoquinoline rings of CKI-7 bound to APH(39)-IIIa or APH(9)-Ia
(Figure 3A).
The linker region between the N- and C-terminal lobes of the
APH enzymes plays an important role in the binding of the
isoquinoline or adenine ring. The N1 and N6 of the adenine ring
form hydrogen bond interactions with the main chain amide of
Ala93 (APH(39)-IIIa numbering) and carbonyl of Ser91, respec-
tively [8]. Although the sole cyclic nitrogen in the isoquinoline,
N2, and the adenine, N1, are located in different positions of the
ring structure, CKI-7 is positioned in such a way that N2 of the
isoquinoline overlays with N1 of the adenine ring in the
nucleotide. Consequently, an interaction analogous to that
between N1 of the adenine and the linker amide is observed
between N2 of the isoquinoline and the amide of Ala93 in
APH(39)-IIIa or Ile103 in APH(9)-Ia. The conformation of the
linker region between the N- and C-terminal lobes appears to have
an impact on the binding orientation of the adenine or
isoquinoline ring. Comparison of the linker in the nucleotide-
and CKI-7-bound complexes of APH reveals that this segment in
APH(39)-IIIa is located closer to the loop connecting helix a2 and
strand b4 behind the adenine-binding pocket, thereby creating a
more open nucleotide-binding site. The difference in the
positioning of the shorter linker region in APH(9)-Ia renders a
deviation in the location of Pro101 and Ile103 from their
counterparts in APH(39)-IIIa, thus leading to a corresponding
and necessary change in the binding orientation of the adenine or
isoquinoline ring in order to maintain the hydrogen bond between
the cyclic nitrogen and the main chain amide.
The remainder of the CKI-7 inhibitor, the aminoethyl-
sulfonamide, adopts different conformations when bound to the
Figure 2. Nucleotide/inhibitor binding sites of APH(39)-IIIa and APH(9)-Ia. The CKI-7- and nucleotide-bound APH(39)-IIIa are shown in
cartoon representation in panels A and C respectively; The CKI-7- and nucleotide-bound APH(9)-Ia are shown in cartoon representation in panels B
and D, respectively. (A) CKI-7 bound to APH(39)-IIIa in magenta sticks and its simulated annealing Fo-Fc omit map, contoured at 2.5s, are shown.
Tyr42, which forms stacking interactions with the isoquinoline, and Ala93, which hydrogen bonds with the inhibitor, are shown in sticks. (B) CKI-7
bound to APH(9)-Ia in dark blue sticks and its simulated annealing Fo-Fc omit map, contoured at 2.5s, are shown. Phe50 whose aromatic ring stacks
with the isoquinoline, and Ile103, which forms hydrogen bond interactions with the inhibitor, are shown in sticks. (C,D) Comparison of the inhibitor-
and nucleotide-bound APHs. The homologous ePK gly-rich loop is highlighted in green for nucleotide-bound APH(39)-IIIa (C) and red for APH(9)-Ia
(D). Tyr42 in APH(39)-IIIa and Phe50 in APH(9)-Ia, that stacks the adenine ring of the nucleotide are shown in sticks and their carbon atoms are colored
green for APH(39)-IIIa (C) and red for APH(9)-Ia (D). The CKI-7-binding sites are delineated by surface representation in their respective enzymes. CKI-7
bound to APH(39)-IIIa and APH(9)-Ia are colored as in panels A and B. CKI-7 binds to the same region and in an analogous manner as the nucleotide to
each of the enzyme. The phosphates of the nucleotide are buried in the surface representing the homologous gly-rich loop in the presence of CKI-7.
doi:10.1371/journal.pone.0019589.g002
CKI-7-Bound Structures of Two APH Enzymes
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an extended conformation and it is situated just beyond the ribose-
binding area, toward the solvent exposed opening of the ATP-
binding pocket (Figure 2A and 3A). Alternatively, using the
terminology of the different compartments in the ATP-binding site
of ePK, the aminoethyl-sulfonamide lies adjacent to the ribose-
binding pocket, bordering the specificity surface [23] or the
entrance pocket [24]. This portion of the inhibitor is more flexible
than the isoquinoline ring as reflected by the relatively higher
thermal factors. Two hydrogen bonds are observed between this
section of the CKI-7 and the APH(39)-IIIa (Figure 2A). One of
which is found between one of the oxygen atoms of the sulfonyl
group (O2S) and the hydroxyl group of Tyr42. The second
hydrogen bond is formed between the terminal nitrogen of the
aminoethyl tail, N29, and the main chain carbonyl of Ser194. An
analogous interaction is observed in the APH(39)-IIIa-nucleotide
complex between the carbonyl of Ser194 and the O39 of the
ribose, which approximately overlaps the N29 of CKI-7. In
APH(9)-Ia, the aminoethyl group of the inhibitor is positioned in
the entrance pocket [24] or the solvent-exposed side of the
adenine-binding pocket and it points back at itself forming an
intramolecular interaction with the equatorial sulfonyl oxygen
atom (O2S) (Figure 2B,3A). The inhibitor also makes a second
interaction with the linker region of APH(9)-Ia via the Nb of the
aminoethyl tail and the main chain carbonyl of Ile103. No
interactions, direct or water-mediated, are observed between the
linker of APH(39)-IIIa and the aminoethyl of CKI-7 since the
linker is one residue longer in APH(39)-IIIa and is situated over
7A ˚ away from the binding pocket compared to the equivalent in
APH(9)-Ia (Figure 3A).
Comparison of CKI-7-bound APHs and casein kinase 1
The crystal structure CK1 in complex with CKI-7 has been
determined [25] (Figure 1C). Here, CKI-7 also occupies the ATP-
binding cleft of CK1, and the overall structures of the inhibitor-
and nucleotide-bound CK1 are the same, differing slightly in the
glycine-rich loop, analogous to what is observed for APH(39)-IIIa
and APH(9)-Ia. The isoquinoline ring of the inhibitor is coplanar
with the adenine moiety of ATP and the aminoethyl-sulfonamide
points away from the ribose toward the solvent accessible opening
of the binding pocket. When the CKI-7-bound structures of
APH(39)-IIIa, APH(9)-Ia, and CK1 are superposed using the
coordinates of conserved active site residues, it is apparent that the
plane of the isoquinoline ring in the CK1 structure differs from
that observed in APH(39)-IIIa by a rotation of approximately 40 ˚
(Figure 3B) but is nearly coplanar to that in APH(9)-Ia (Figure 3C),
analogous to the binding of the adenine ring in the nucleotide-
bound enzymes [20]. Furthermore, the linker region of CK1, in
particular the N-terminal section which form hydrogen bond
contacts with the ring structure of the ligand, superpose well with
that of APH(9)-Ia.
The hydrogen bond between the cyclic nitrogen and a main
chain amide (Leu88 in CK1) in the linker of the enzyme is also
present in the CKI-7-bound CK1 (Figure 3B,C). The equivalent
hydrogen bond observed between N1 of adenine and the tethering
segment in the three enzymes is conserved in all adenine-binding
to ePKs [26]. This hydrogen bond is not unique to isoquinoline-
sulfonamide type inhibitors binding to the three enzymes discussed
here. A majority of ePK crystal structures complexed with an
ATP-competitive inhibitor form at least one hydrogen bond with
residues in the linker region, mimicking the ones between N1 and/
or the exocyclic N6 of the adenine and the enzyme [23]. The
significance of the hydrogen bond interaction is corroborated by a
previous observation in which naphthalene sulfonamide molecules
did not display selective inhibition against ePKs until the all-
carbon naphthalene ring is substituted with an isoquinoline [27].
In contrast to APH(39)-IIIa in which the aminoethyl tail adopts
an extended conformation, this groups adopts the same confor-
mation and is placed in the equivalent area as that in APH(9)-Ia.
The aminoethyl tail found in the CK1 structure bends back
toward the sulfonyl group and forms an intramolecular interaction
between the terminal nitrogen atom and the equatorial sulfonyl
oxygen atom. Deviating slightly from the binding mode of CKI-7
to APH(9)-Ia, the contact between the Nb of the aminoethyl and
carbonyl of Leu88 located in the linker of the enzyme is achieved
Figure 3. Comparisons of CKI-7 binding to APH(39)-IIIa, APH(9)-Ia and CK1. The structures are superposed using the conserved residues
among the enzymes. (A) Superposition of CKI-7-bound APH(39)-IIIa and APH(9)-Ia. The conserved active site residues between APH(39)-IIIa and
APH(9)-Ia are colored dark grey and light grey respectively. The APH(39)-IIIa-bound CKI-7 is shown as magenta sticks and the APH(9)-Ia-bound CKI-7 is
shown as dark blue sticks. The rotation between the planes of the isoquinoline rings of CKI-7 bound to APH(39)-IIIa and APH(9)-Ia is approximately
40u. (B) Superposition of CKI-7-bound APH(39)-IIIa and CK1. The same degree of rotation as that observed between the isoquinolines of the APH(39)-
IIIa- and APH(9)-Ia-bound CKI-7 is observed here. (C) Superposition of CKI-7-bound APH(9)-Ia and CK1. The CKI-7 isoquinoline rings are coplanar. In
panels (B) and (C), APH(39)-IIIa and APH(9)-Ia are colored as in panel A, and CK1 is colored in cyan. The residues that interact with CKI-7 and those with
dissimilar properties from ePK nucleotide-binding site are shown in sticks. Hydrogen bond interactions between CKI-7 and CK1 are illustrated as dash
lines. Water molecule is represented by a red sphere.
doi:10.1371/journal.pone.0019589.g003
CKI-7-Bound Structures of Two APH Enzymes
PLoS ONE | www.plosone.org 4 May 2011 | Volume 6 | Issue 5 | e19589via a water molecule, compared to a direct interaction observed in
APH(9)-Ia.
Implications for Inhibitor Design and Adjuvant
Development
Previous studies, together with the present report, indicate that
CKI-7 can be exploited as a lead compound for APH inhibitor
development. Two requirements must be met, however, to make
such an inhibitor potentially useful in drug-adjuvant therapy: (1)
despite the structural homology between APHs and ePKs, an
inhibitor should be selective for the bacterial resistance enzymes.
(2) Given that resistant pathogens can harbor multiple APH
enzymes, it is desirable that such an inhibitor has a broad-
spectrum of activity against various APHs. It is encouraging to
note that CKI-7 is only able to effectively inhibit a few ePKs [28]
while it can modestly inhibit at least three different APHs. This
suggests that the two requirements for an adjuvant application
might be achievable. The structural data for the three kinase-CKI-
7 complexes provides further information to assess feasibility.
With respect to achieving selectivity for APHs vs. ePKs, the
three kinase-CKI-7 structures reveal ample differences in binding,
as also reflected in the variance in the enzymes’ Ki values, to
confidently suggest that inhibitors based on the isoquinoline
scaffold can be developed for either APH(39)-IIIa or APH(9)-Ia
that do not bind to CK1 and likely other ePKs. This confidence is
fueled by the extensive expertise in the development of specific
inhibitors to the ATP-binding pocket of ePKs, which has shown
that sequence divergence in this part of the enzyme is a good
predictor of whether selectivity can be obtained [24,29,30,31] The
ATP-binding pocket of APH(39)-IIIa is distinct from CK1 and
other ePKs as it a possesses a large aromatic residue (Tyr42) that
forms stacking interactions with the isoquinoline moiety. Addi-
tionally, the combination of a large nonpolar gatekeeper residue
(Met90), a nonpolar residue in the entrance pocket (Leu97) and
the absence of a glycine residue in the hinge region that can induce
backbone conformation changes, results in a pocket that is
predicted to be suitable for selective targeting. Similarly, the
nucleotide-binding pocket in APH(9)-Ia shares many of these
distinguishing features with APH(39)-IIIa, though it has a polar
residue in the entrance pocket (Asn107), making this pocket
somewhat less different from a few ePKs.
Regarding the feasibility of obtaining an inhibitor with broad-
specificity against various APHs, the structural data presented here
is less encouraging. The differences observed in the nucleotide-
binding pocket between APH(39)-IIIa and APH(9)-Ia are similar in
magnitude as those between APH(39)-IIIa and CK1. This in itself
is not necessarily problematic as long as those differences do not
compromise their distinctive features from ePKs. However, one of
the most distinguishing features of many APHs, i.e. the aromatic
residue that forms stacking interactions with the isoquinoline
moiety, has differential impacts on inhibitor binding in the two
APH structures studied. As a result, the orientation and
conformation of CKI-7 observed in APH(9)-Ia mirrors what is
seen in CK1. These observations illustrate the diversity in the
architectures of the ATP-binding pocket present within the APH
family of enzymes, which will undoubtedly complicate develop-
ment of broad-spectrum inhibitors. On the other hand, it must be
realized that the selection of APH(39)-IIIa and APH(9)-Ia for these
studies impacts the conclusions with respect to the feasibility of
adjuvant development. As mentioned, APH(9)-Ia is an atypical
member of the APH family, and while it provides valuable insights
into the extent of the diversity present in nucleotide-binding
pockets of APH enzymes, it does not necessarily reflect the
diversity of nucleotide-binding pockets likely encountered in
clinical settings. Nonetheless, our observations lead us to contend
that a universal inhibitor for all APHs targeting the nucleotide-
binding pocket may not be feasible, but the contrasting details
between APH(39)-IIIa, APH(9)-Ia and ePKs suggests that selective
inhibitors that target a subset of APHs is attainable.
Materials and Methods
Enzyme Inhibition Kinetics
The inhibition constant of CKI-7 was determined by first
obtaining the Michaelis-Menten parameter, Km
apparent, at various
concentrations of the inhibitor. Steady-state kinetics was examined
using the procedure previously reported by McKay et al. [16]. In
brief, activity of APH(9)-Ia is monitored by coupling the release of
ADP from the phosphorylation step of APH(9)-Ia to the reactions
of pyruvate kinase and lactate dehydrogenase. The rate of APH(9)-
Ia phosphorylation corresponds to the decrease in absorbance at
340 nm due to the exhaustion of NADH in the conversion from
pyurvate to lactate by lactate dehydrogenase. The enzyme assay
was performed in the presence of five concentrations of CKI-7 (0,
50, 100, 400, and 800 mM) at near saturation level of the substrate
spectinomycin (1 mM) and a range of ATP concentrations. All
assays were conducted in triplicates with a final reaction volume of
200 mL and measured using a SPECTRAMax 190 (Molecular
Devices) 96-well plate spectrophotometer. Km
apparent was calcu-
lated from equation 1 with non-linear regression using Grafit
version 5.0.1 software.
vo~
kcat½Et ½S 
K
apparent
m z½S  ð1Þ
The inhibition constant, KI, was determined from a plot of
Km
apparent versus CKI-7 concentrations, where the x-intercept
gives the value of –KI.
Kapparent
m ~Km 1z
I ½ 
KI

ð2Þ
Crystallization and Data Collection
APH(39)-IIIa was expressed and purified using previously
established methods [16]. Procedures for the crystallization and
data collection of APH(39)-IIIa-CKI-7 complex have been pub-
lished [32]. Briefly, crystals of APH(39)-IIIa-CKI-7 complex were
grown using polyethylene glycol (PEG) 3000 as the precipitant and
diffracting crystals were obtained by successive cycles of microseed-
ing. Data were collected under cryogenic conditions from a single
crystal at beamline X8C of the National Synchrotron Light Source,
Brookhaven National Laboratory (Upton, NY), equipped with an
ADSC Quantum CCD detector.
APH(9)-Ia was expressed and purified using protocols reported
[33]. Details of the initial crystallization strategy of APH(9)-Ia in
the presence of CKI-7 has been described [33]. Crystals were
obtained in drops containing 2 mL of APH(9)-Ia-CKI-7 mixture,
2 mL of well solution consisting 15% PEG 3350 and 0.2 M
calcium acetate, and 0.4 mL of 50 mM manganese chloride.
Diffraction data from a single crystal were collected under
cryogenic conditions on a Rigaku rotating copper anode generator
equipped with Osmic confocal optics and an R-AXIS IV
++ image-
plate detector system. Prior to data collection, the crystal was
CKI-7-Bound Structures of Two APH Enzymes
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3350, 0.2 M calcium acetate and 1 M sodium formate. Processing
of diffraction data for both crystals was performed using HKL2000
[34]. A summary of data collection and processing statistics is
shown in Table 1.
Structure Determination and Refinement
Despite different crystal growth conditions, APH(39)-IIIa-CKI-7
crystal was isomorphous with APH(39)-IIIa-ADP crystals. Hence,
the APH(39)-IIIa-ADP structure (PDB ID 1J7L) [8], excluding the
ligand and water molecules, was used as the starting model for the
refinement of APH(39)-IIIa-CKI-7 complex in the Crystallography
and NMR System (CNS) program [35]. After rigid body
refinement and an initial cycle of positional and grouped thermal
factor refinement, one molecule of CKI-7 was modeled in each
active site in the space where sa-weighted difference maps (2Fo-Fc
and Fo-Fc) displayed positive electron density. The stereochemical
parameters for CKI-7 used in subsequent refinement were based
on the conformation of the inhibitor found in the crystal structure
of casein kinase 1 (PDB ID 2CSN) [25] in conjunction with values
from the energy minimized conformation obtained from the
molecular mechanics program MM2 [36,37] implemented in
CambridgeSoft Chem3D software. Upon inspection, several
regions required remodeling due to considerable deviations from
the difference density maps. Cycles of positional and individual
thermal factor refinement was alternated with manual refitting
using the program O [38] and incorporation of solvent molecules.
The process was continued in the programs PHENIX [39] and
COOT [40] until no further improvement in model statistics could
be obtained.
The structure of CKI-7-bound APH(9)-Ia was solved by
molecular replacement using Phaser [41] as implemented in the
CCP4 software suite [42] and the apo structure of APH(9)-Ia (PDB
ID 3I1A) as the starting model. A solution of the proper position
and orientation of the inhibitor-bound molecule was obtained only
when the search model was input as two entities – the N-terminal
lobe (residues 3–199) and the C-terminal lobe (residues 200–330).
Following several cycles of positional and grouped B-factor
refinement, a molecule of CKI-7 was placed in the nucleotide-
binding site according to the observed positive difference maps.
The same stereochemical parameters used for APH(39)-IIIa-bound
CKI-7 were applied to the APH(9)-Ia-bound inhibitor for
structure refinement. Iterative cycles of positional and individual
thermal factor refinement using CNS are intercalated with manual
adjustments along with the addition of water molecules. Several
regions (residues 27–40, 53–60, 89–97, and 297–309) that display
substantial difference between the model and electron density were
manually rebuilt using the program O [38] according to difference
density maps and simulated annealing omit maps. Final
refinement statistics for the inhibitor-bound structures of both
APH enzymes are summarized in Table 1.
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